(IDNA) Genomics Immunology - Overview
Etf: Genomics, Immunology, Bioengineering, Healthcare, ETF
| Risk 5d forecast | |
|---|---|
| Volatility | 22.7% |
| Relative Tail Risk | 1.25% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.96 |
| Alpha | 18.58 |
| Character TTM | |
|---|---|
| Beta | 0.809 |
| Beta Downside | 0.644 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.60% |
| CAGR/Max DD | 0.29 |
Description: IDNA Genomics Immunology January 25, 2026
The iShares Genomics Immunology and Healthcare ETF (NYSE ARCA: IDNA) commits at least 80% of its capital to the securities that compose its underlying index-or to assets that mirror those securities’ economic characteristics-and may allocate up to the remaining 20% to futures, options, swaps, cash, and cash equivalents. The index tracks developed- and emerging-market firms positioned to profit from long-term growth in genomics, immunology, and bio-engineering.
As of Q4 2024, IDNA holds roughly $1.2 billion in assets under management, carries an expense ratio of 0.45 %, and its top five holdings (e.g., Illumina, Moderna, Regeneron, CRISPR Therapeutics, and Gilead Sciences) together represent about 22 % of the portfolio. The global genomics market is projected to expand at a CAGR of ≈ 12 % through 2030, while immunotherapy sales are expected to rise 10 % YoY, driven by an aging population and increasing venture capital flow into biotech (VC funding hit a record $41 billion in 2023). These macro trends underpin the ETF’s sector exposure.
For a deeper, data-rich assessment of IDNA’s risk-adjusted performance, you may want to explore the ValueRay platform’s analytical tools.
Altman Z''
Beneish M
| DSRI: none (Receivables none/none, Revenue 0.0/0.0) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: none (Revenue 0.0 / 0.0) |
| TATA: none (NI 0.0 - CFO 0.0) / TA none) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of IDNA shares?
Over the past week, the price has changed by +1.96%, over one month by +3.82%, over three months by +15.38% and over the past year by +29.91%.
Is IDNA a buy, sell or hold?
What are the forecasts/targets for the IDNA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
IDNA Fundamental Data Overview February 20, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 148.5m USD (148.5m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 148.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 148.5m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.90% (E(148.5m)/V(148.5m) * Re(8.90%) + (debt-free company))
Discount Rate = 8.90% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)